XLO Stock Summary and Trading Ideas (Xilio Therapeutics | NASDAQ:XLO)

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Xilio Therapeutics trades on the NASDAQ stock market under the symbol XLO.

As of September 23, 2024, XLO stock price declined to $0.76 with 58,394 million shares trading.

XLO has a beta of -0.72, meaning it tends to be less sensitive to market movements. XLO has a correlation of 0.01 to the broad based SPY ETF.

XLO has a market cap of $33.22 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that XLO belongs to (by Net Assets): VTI, VXF, IWC.

XLO has underperformed the market in the last year with a price return of -66.6% while the SPY ETF gained +31.5%. XLO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.7% and -7.0%, respectively, while the SPY returned +5.1% and +5.7%, respectively.

XLO support price is $.72 and resistance is $.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XLO stock will trade within this expected range on the day.